Exhibit 99.1 TD SYNNEX Reports Fiscal 2024 Fourth Quarter and Full Year Results FREMONT, CA and CLEARWATER, FL, January 10, 2025 – TD SYNNEX (NYSE: SNX) today announced financial results for the fiscal fourth quarter and fiscal year ended November 30, 2024. Consolidated Financial Highlights for the Fiscal 2024 Fourth Quarter: GAAP ($ in millions, except earnings per share) Q4 FY24 Q4 FY23 Net Change from Q4 FY23 Revenue $ 15,844.6 $ 14,407.3 10.0 % Gross profit $ 1,040.9 $ 1,018.6 2.2 % Gross margin 6.57 % ...

Exhibit 99.1 Savers Value Village, Inc. Announces Preliminary Fourth Quarter and Full Year Net Sales and Participation in the 27 Annual ICR Conference th Reaffirms Previous Outlook for Adjusted EBITDA 1 Bellevue, WA – January 10, 2025 – Savers Value Village, Inc. (NYSE: SVV), (the "Company") today announced preliminary net sales for the thirteen weeks ended December 28, 2024 (the "fourth quarter") and the fifty-two weeks ended December 28, 2024 ("fiscal 2024") in conjunction with the Company's participation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Date of Report (Date of earliest event reported): January 10, 2025 BARINTHUS BIOTHERAPEUTICS PLC (Exact name of registrant as specified in its charter) England and Wales 001-40367 Not Applicable (State or other jurisdiction of incorporation) Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (Commission File Number) (I.R.S. Employer Identification No.) Barinthus Biotherapeutics plc Unit 6-10, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 AXOGEN, INC. (Exact Name of Registrant as Specified in Charter) Minnesota (State or Other Jurisdiction of Incorporation or Organization) 001-36046 (Commission File Number) 41-1301878 (I.R.S. Employer Identification No.) 13631 Progress Boulevard, Suite 400 Alachua, Florida (Addr ...

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization -- Company also reports preliminary unaudited 2024 revenue of $701.0 million -- Parsippany, NJ., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced its five-year growth-oriented plan to accelerate ...

EXHIBIT 2.1 Execution version and AKOYA BIOSCIENCES, INC. Dated as of January 9, 2025 TABLE OF CONTENTS | ARTICLE 1 DEFINITIONS | | 2 | | --- | --- | --- | | 1.01 | Definitions | 2 | | 1.02 | Other Definitional Provisions | 15 | | | ARTICLE 2 THE MERGER | 16 | | 2.01 | Shares of Merger Sub | 16 | | 2.02 | The Merger | 16 | | 2.03 | Closing | 17 | | 2.04 | Effective Time | 17 | | 2.05 | Effects of the Merger | 17 | | 2.06 | Certificate of Incorporation and Bylaws | 17 | | 2.07 | Directors and Officers of the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2025 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) 25 Mall Road, Suite 203 Burlington, Massachusetts 01803 (Address of principal executive offices) (Zip Code) (Commission File Number) Delaware 001-38293 4 ...

M=>7>I ))475-1)55216-17)562)/-8)4#2/70)4296,-5'-3/-1)(4-'-1+'6-215%1( ((-6-21%/256 %8-1+5$,-/)4-8-1+1'4)0)16%/%4.)6-1+18)560)165 203%1;)67415126,)4<- -//-2162 ,%4),2/()45-1 ,%4))374',%5)5 $,-/)216-17-1+62(8%1')42%()4-5'-3/-1)(%3-6%///2'%6-214-24-6-)5 "3(%6)5-5'%/ 76/22.$-6,)(7')(4296,:3)'6%6-215 *24)6 %/)5%1(3)4%6-1+ 1'20)2*16)434-5)%1(75-1)55)529)45)3246)( %1(29)41(2*203%4%&/) 7-(%1')1'4)%5)53)4%6-1+%5,/29%1(4))%5,/29!%4+)65 | | | | | 9?JHI:9 6GC>CAJI:9):I$C8DB: 'DHH+:G.=6G: | | --- | --- | --- | --- | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39272 E2open Parent Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 86-1874570 (State or other ...

Exhibit 99.1 ROYALTY PHARMA TO HIGHLIGHT ACCOMPLISHMENTS AND PROVIDE BUSINESS UPDATE AT 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE NEW YORK, NY, January 10, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2024 outlook for Portfolio Receipts. Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer, will discuss these updates on January 14, 2025 as part of a webcast presentation to be held a ...